The University of New Mexico Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care are utilizing ImmunoID NeXT platform for their ongoing ovarian cancer clinical trial.
The study is being conducted at multiple centers across the United States and will employ the platform from Personalis that offers biomarker discovery applications.
The teams opted for the ImmunoID NeXT platform to investigate biomarkers of response to a combination of AstraZeneca’s olaparib (Lynparza) and tremelimumab in women with recurrent BRCA-deficient ovarian cancers.
The trial design reflects on evidence from previous clinical trial results evidencing that immune priming with targeted cytotoxic therapy using a PARP inhibitor might sensitize ovarian tumors to added immune therapy.
Dr. Sarah Adams, Associate Professor, Division of Gynecologic Oncology at the UNM Comprehensive Cancer Center reports, “We are delighted to collaborate with Personalis on this study.” Dr. Adams continued, “Comprehensive immune-profiling will inform on biomarkers of response for this experimental treatment in women with BRCA1 or BRCA2 germline mutated ovarian cancers, for which there aren’t standard curative measures.”
What Value does ImmunoID NeXT add?
Personalis reports that the system provides broad integration of both DNA and RNA across approximately 20,000 genes to identify biomarker signals associated with a variety of biologic features, including tumor escape mechanisms, immune repertoire, profile, neoantigen load, tumor mutational burden, etc., reports the company in a press release. The financial terms were not disclosed.
Who is Personalis?
Based in Silicon Valley, California, Personalis combines expertise both in the technology of sequencing and interpretation, with an extensive history of peer reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both in variant detection and interpretation.
Personalis, Inc. is partnering with biopharma to develop and commercialize the next generation of cancer immunotherapies. They provide advanced genomic sequencing and analytics for immuno-oncology. Their patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products and makes it possible for them to achieve augmented coverage of difficult-to-sequence genomic regions often missed with the use of conventional sequencing techniques, in addition to more comprehensive and accurate genomic data. ACE ImmunoID, their universal platform for immuno-oncology, combines augmented whole exome and transcriptome assays with analytics that capture neoantigens, elucidate the tumor microenvironment, and identify mechanisms of tumor escape. The company’s Clinical Laboratory is GxP aligned as well as CLIA’88 and CAP accredited. Financially, they presently enjoy a $523 million market capitalization based on about $48 million in revenue as markets expect big growth. They presently are operating at a loss.